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Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, 
but is not required for maintenance of resistance 
Rachel Alexandra O’Keefe 
 
Abstract 
The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent 
that has been FDA approved for the treatment of head and neck squamous cell carcinoma 
(HNSCC). Currently, there are no biomarkers used in the clinic to predict which HNSCC tumors 
will respond to cetuximab, and even in tumors that regress with treatment, acquired resistance 
occurs in the majority of cases. Though a number of mechanisms of acquired resistance to 
cetuximab have been identified in preclinical studies, no therapies targeting these resistance 
pathways have yet been effectively translated into the clinic. To address this unmet need, we 
examined the role of the cytokine interleukin 6 (IL-6) in acquired cetuximab resistance in 
preclinical models of HNSCC. We found that IL-6 secretion was increased in PE/CA-PJ49 cells 
that had acquired resistance to cetuximab compared to the parental cells from which they were 
derived. However, addition of exogenous IL-6 to parental cells did not promote cetuximab 
resistance, and inhibition of the IL-6 pathway did not restore cetuximab sensitivity in the 
cetuximab-resistant cells. Further examination of the IL-6 pathway revealed that expression of 
IL6R, which encodes a component of the IL-6 receptor, was decreased in cetuximab-resistant 
cells compared to parental cells, and that treatment of the cetuximab-resistant cells with 
exogenous IL-6 did not induce phosphorylation of signal transducer and activator of transcription 
3, suggesting that the IL-6 pathway was functionally impaired in the cetuximab-resistant cells. 
These findings demonstrate that, even if IL-6 is increased in the context of cetuximab resistance, 
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it is not necessarily required for maintenance of the resistant phenotype, and that targeting the 
IL-6 pathway may not restore sensitivity to cetuximab in cetuximab-refractory HNSCC. 
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Chapter 1:  Introduction 
1.1 HNSCC incidence and etiology 
Head and neck cancer, which arises in the oral cavity, larynx, and pharynx, is the sixth 
most common cancer worldwide [1,2]. The majority (~90%) of head and neck tumors are 
squamous cell carcinomas (HNSCC) [1,3]. Each year, over half a million patients are diagnosed 
with HNSCC, and despite aggressive therapy, the five-year survival rate for patients with this 
cancer has hovered around 50% for decades [1,4–7]. 
The overall incidence of HNSCC has declined in recent decades, due at least in part to a 
reduction in tobacco use in this time period [1]. However, behavioral and environmental factors 
that increase the risk of developing HNSCC persist worldwide, with the use of tobacco, alcohol 
(which acts synergistically with tobacco), and betel nuts leaving a substantial population at risk 
for developing carcinogen-induced HNSCC [1]. Moreover, the overall decrease in HNSCC 
incidence masks an increase in human papillomavirus (HPV)-associated HNSCC [1,8]. 
HPV-associated head and neck tumors, which occur primarily in the oropharynx [1,3,8], 
arise following infection with high-risk types of human papillomavirus (HPV), particularly HPV-
16 [1,8]. Expression of the viral proteins E6 and E7 promote tumorigenesis primarily by 
inducing degradation of the tumor suppressor proteins p53 and retinoblastoma protein (pRb), 
respectively [1,8]. Patients with HPV-positive HNSCC are younger, on average, and have an 
improved prognosis compared to patients with HPV-negative HNSCC [1,9]. The improved 
prognosis is thought to be due not to the younger average age of patients with HPV-associated 
HNSCC, but to the improved response to chemoradiotherapy in HPV-positive tumors [8]. 
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1.2 Current treatment strategies in HNSCC 
Despite the differences between HPV-positive and -negative HNSCC, including in 
mechanisms of tumorigenesis, response to chemoradiotherapy, and prognosis, there are currently 
no FDA-approved therapies specific to either HPV-positive or -negative HNSCC. This may 
change in the near future, as clinical trials enrolling only HPV-positive or -negative HNSCC are 
being designed based on the results of studies uncovering further differences between HPV-
positive and -negative HNSCC and identifying potential therapeutic targets in their respective 
cohorts. These studies include a recent comprehensive genomic analysis of 279 HNSCC tumors 
by The Cancer Genome Atlas (TCGA) Network that incorporated a comparison between HPV-
positive and -negative HNSCC tumors [10]. 
Currently, although the prescribed treatment for HNSCC varies based on tumor stage and 
anatomical location, platinum-based chemotherapy, radiation, and/or surgery are commonly 
employed [1,6,7,10–15]. In addition, the immune checkpoint inhibitors nivolumab (Opdivo) and 
pembrolizumab (Keytruda), both PD-1-targeted monoclonal antibodies, were FDA approved for 
the treatment of HNSCC in 2016 [3]. To date, the only oncogene-targeted agent that is FDA 
approved for the treatment of HNSCC is cetuximab (Ctx), a monoclonal antibody that targets the 
receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR; also referred to as 
ErbB1), which is overexpressed in up to 90% of HNSCC tumors [5,12,16–18]. 
 
1.3 EGFR signaling and alterations in cancer 
Activation of EGFR occurs when one of its seven ligands binds to its extracellular 
domain and elicits a conformational change that enables dimerization [19–22]. EGFR can 
dimerize with other HER family members or with non-HER family RTKs, including AXL, and 
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the formation of dimers with different partners can modulate the outcome of EGFR activation 
[23–25]. Dimerization facilitates allosteric activation of the kinase domains of the participating 
receptors, promoting transphosphorylation of tyrosine residues in the intracellular domain and 
creating binding sites for downstream effectors, facilitating their activation [20,21,24]. Among 
the signaling pathways downstream of EGFR that have been shown to mediate EGFR-induced 
transformation are the phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin 
(PI3K/Akt/mTOR), RAS/RAF/mitogen-activated protein kinase kinase/extracellular signal-
regulated kinase (RAS/RAF/MEK/ERK), and Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) pathways [19,25–29]. The ability of EGFR to activate these signaling 
pathways is co-opted by cancer cells, particularly those in which EGFR is overexpressed and/or 
mutated, to drive tumorigenesis, to promote tumor cell survival and metastasis, to enable 
immune evasion, and to mediate resistance to chemotherapy. 
Aberrant activation of EGFR occurs in many cancer types, although the alterations that 
lead to this hyperactivation vary. Some cancers exhibit overexpression and/or hyperactivation of 
wild-type EGFR, while activating mutations are observed in others [19,25,30]. Activating 
mutations, sometimes co-occurring with amplification of the EGFR gene, have been observed in 
non-small cell lung cancer (NSCLC) and glioblastoma [25,31–33]. Oncogenic fusion proteins 
containing the N-terminal domain of EGFR were also recently identified in lung adenocarcinoma 
[34]. In HNSCC, activating mutations in EGFR are rarely observed, but amplification of wild-
type EGFR occurs and often results in overexpression of the EGFR protein, which serves as an 
oncogenic driver [19,24,25,30,35]. Transcriptional upregulation of EGFR in the absence of gene 
amplification has also been reported in HNSCC [25]. EGFR overexpression occurs in up to 90% 
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of HNSCC tumors, and EGFR has been established as an oncogenic driver in this disease 
[24,25,36]. 
 
1.4 Cetuximab:  An EGFR-targeted therapy used to treat HNSCC 
Cetuximab (Erbitux) is a human-mouse chimeric monoclonal immunoglobulin G1 (IgG1) 
antibody that recognizes the extracellular domain of EGFR [17,37–39]. Binding of cetuximab to 
EGFR prevents ligand binding and activation of the receptor, thereby abrogating EGFR signaling 
[40]. Cetuximab also triggers internalization of EGFR, resulting in a reduction of cell-surface 
EGFR levels, and, often, degradation of the receptor [5]. In addition, as an IgG1 monoclonal 
antibody and, as such, can induce antibody-dependent cell-mediated cytotoxicity (ADCC) 
[11,38]. In ADCC, the low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIA; 
CD16) on natural killer cells binds to the constant region of IgG1-isotype antibodies. This 
antibody-NK cell interaction triggers the release of NK cell proteins that induce tumor cell lysis 
[14,15,41,42]. 
Cetuximab was first approved for the treatment of HNSCC by the FDA in 2006, when the 
results of a Phase 3 clinical trial comparing cetuximab plus radiotherapy with radiotherapy alone 
in a cohort of 424 patients with locoregionally advanced HNSCC were reported [13]. This 
clinical trial demonstrated that addition of cetuximab to high-dose radiotherapy improved 
locoregional control, overall survival, and progression-free survival compared to high-dose 
radiotherapy alone [13]. Also in 2006, cetuximab was approved as a single agent for the 
treatment of patients with recurrent/metastatic HNSCC whose tumors had previously progressed 
on platinum-based chemotherapy [43]. (Notably, the response rate to single-agent cetuximab in 
this trial was 13% [43].) Subsequently, cetuximab was FDA approved in combination with 
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platinum-based chemotherapy based on results from a clinical trial in which 442 patients with 
recurrent/metastatic HNSCC were assigned to be treated with cisplatin or carboplatin plus 
fluorouracil alone or in combination with cetuximab [11]. The addition of cetuximab to this 
chemotherapy regimen improved overall survival compared to chemotherapy alone [11]. 
It should be noted that, while cetuximab has been shown to improve response in 
combination with chemotherapy in HNSCC, other EGFR inhibitors have not fared as well in 
clinical trials in this disease, despite a number of studies demonstrating that erlotinib and 
panitumumab are effective in preclinical models of HNSCC [11,25,36,44,45]. It has been 
suggested, though not proven, that the enhanced clinical efficacy of cetuximab compared to other 
EGFR inhibitors tested in HNSCC may be explained, at least in part, by its ability to promote 
immune-mediated tumor clearance via induction of ADCC [44,45]. (Panitumumab, as an IgG2-
isotype antibody, is less effective at inducing natural killer cell-mediated ADCC than cetuximab 
[26,45,46].) 
 
1.5 Challenges in using cetuximab to treat HNSCC 
Despite extensive evidence supporting EGFR as a therapeutic target in HNSCC, the 
response rate for single-agent cetuximab is below 20% in this disease [43,47], and therapy-
resistant tumors arise in the majority of cetuximab-treated HNSCC patients [38]. Identification 
and targeting of pathways that mediate intrinsic and acquired cetuximab resistance could 
augment the effectiveness of treatment with this drug. 
An ongoing challenge in the treatment of HNSCC is the lack of a predictive biomarker(s) 
for response to cetuximab. Because cetuximab targets EGFR, it was initially hypothesized that 
high tumoral expression of EGFR would identify tumors most likely to respond to cetuximab; 
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however, this has not proven to be the case [48–50]. Looking to colorectal cancer, another 
malignancy for which cetuximab has been FDA approved, tumors harboring activating mutations 
in KRAS, NRAS, or BRAF are often resistant to cetuximab, and mutations in these genes serve as 
a negative predictive biomarker for cetuximab response [27,48,51]. In HNSCC, however, 
activating mutations in KRAS, NRAS, and BRAF are rarely observed, and though activating 
mutations in HRAS have been implicated in cetuximab resistance in HNSCC [52,53], HRAS 
alterations are observed in only 5% of HNSCC tumors and its robustness as a negative predictive 
biomarker remains unproven [10]. Identification of a predictive biomarker(s) could improve 
outcomes by enabling identification of a subset of patients whose tumors are likely (or unlikely) 
to respond to cetuximab. Results of a recent clinical trial designed to identify potential predictive 
biomarkers of response to cetuximab-containing therapy in HNSCC prompted the project that 
constitutes the bulk of my dissertation and will be discussed in Chapter 2 [48]. 
Acquired resistance to cetuximab is another major obstacle in the effective treatment of 
HNSCC. Even in tumors that initially respond to cetuximab-containing therapy, acquired 
resistance to cetuximab emerges in the majority of cases, and there are currently no therapeutic 
avenues to overcome resistance once it develops. 
 Mechanisms of resistance to cetuximab are varied, but generally promote resistance by 
restoring activation of the oncogenic signaling pathways downstream of EGFR, often via 
compensatory activation of alternative receptors and/or activating mutations in components of 
these downstream signaling pathways. 
Increased expression and activation of alternative receptor tyrosine kinases (RTKs) is 
frequently observed in the context of EGFR inhibition and is a common mechanism of resistance 
to cetuximab. Compensatory activation of not only human epidermal growth factor receptor 
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(HER)2 and HER3, two other members of the HER family of RTKs, but also non-HER family 
RTKs, such as MET and AXL, has been implicated in cetuximab resistance [54–56]. 
We recently reported activation of alternative RTKs in cetuximab-resistant clones derived 
from three different cetuximab-sensitive HNSCC cell lines (Cal33, FaDu, and PE/CA-PJ49) 
[56]. Though the specific RTKs activated varied among the cell lines, each cetuximab-resistant 
clone exhibited increased activation of alternative RTKs compared to the parental cells from 
which they were derived. The cetuximab-resistant cells also exhibited increased expression of 
the bromodomain and extra-terminal (BET) family member bromodomain-containing protein 4 
(BRD4), an epigenetic ‘reader’ protein that had previously been shown to promote transcription 
of RTKs [56–58]. Treatment of the cetuximab-resistant cells with JQ1, a BET bromodomain 
inhibitor that potently and selectively targets BRD4, re-sensitized cetuximab-resistant FaDu and 
PE/CA-PJ49 to cetuximab [56,59]. Re-sensitization to cetuximab corresponded with a decrease 
in RTK expression in JQ1-treated cetuximab-resistant HNSCC cells [56]. Thus, BRD4 inhibition 
may be a viable therapeutic strategy to target multiple RTKs that have been implicated in 
cetuximab resistance. 
Downstream of EGFR, alterations in the PI3K/Akt/mTOR pathway, particularly 
activating mutations in PIK3CA, have been implicated in resistance to cetuximab in HNSCC 
[52,60], and co-targeting with inhibitors of the PI3K/Akt/mTOR has been shown to enhance the 
anti-tumor effects of cetuximab in preclinical HNSCC models [5,18,60]. Previous work from our 
laboratory has shown that the oncogenic transcription factor STAT3 is aberrantly activated in 
cell line models of acquired resistance [61]. In addition, the ability of cetuximab to inhibit cell 
proliferation was shown to be enhanced in HNSCC cells in which STAT3 was knocked down 
[62]. 
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Although a number of mechanisms of resistance to cetuximab have been identified, these 
efforts have not yet led to an FDA-approved treatment strategy to prevent and/or overcome 
cetuximab resistance. To address this unmet need and the distinct, yet related challenge of 
identifying a predictive biomarker that can detect tumors that are intrinsically resistant to 
cetuximab, we assessed the role of interleukin 6 (IL-6) signaling in acquired resistance of 
cetuximab. Our findings are presented in Chapter 2. 
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Chapter 2:  Interleukin 6 is increased in preclinical HNSCC models 
of acquired cetuximab resistance, but is not required for 
maintenance of resistance 
 
2.1 Introduction 
As discussed in Chapter 1, there are currently no predictive biomarkers to guide selection 
of HNSCC patients whose tumors are likely to respond (or not respond) to cetuximab. 
Expression of EGFR itself cannot predict whether an HNSCC tumor will respond to cetuximab 
[48–50], and activating mutations in KRAS, NRAS, and BRAF that serve as predictive biomarkers 
of resistance to cetuximab in colorectal cancer occur at very low frequencies in HNSCC and thus 
cannot serve as predictive biomarkers in this disease [27,48,51]. Use of a predictive biomarker(s) 
could improve outcomes by informing selection of patients to be treated with cetuximab, 
allowing clinicians to provide cetuximab to HNSCC patients who are likely to benefit from 
treatment with cetuximab without subjecting patients whose tumors are unlikely to respond to 
cetuximab to treatment with this drug. Stratifying patients in this manner requires the 
identification of a biomarker(s) whose expression can reliably predict which HNSCC tumors will 
respond to cetuximab treatment. 
To this end, a recent Phase II clinical trial sought to identify serum biomarkers that could 
predict resistance to a combination of cetuximab and the Src family kinase inhibitor dasatinib in 
HNSCC patients whose tumors had previously progressed on cetuximab-containing therapy [48]. 
In this trial, serum was collected from 13 patients before and after treatment with a combination 
of cetuximab and dasatinib, and the concentrations of four candidate biomarkers (hepatocyte 
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growth factor [HGF], interleukin 6 [IL-6], transforming growth factor alpha [TGF-α], and 
vascular endothelial growth factor [VEGF]) were compared in the pre- and post-treatment 
samples [48]. Of the four candidate serum biomarkers, only IL-6 levels were shown to be 
correlated with resistance to the combination of cetuximab and dasatinib [48], identifying high 
serum IL-6 as a potential predictive biomarker of resistance to cetuximab-containing therapy in 
HNSCC. 
First discovered as a factor that promotes immunoglobulin production by B cells (and 
originally referred to as B-cell stimulatory factor-2) [63], IL-6 has since been frequently 
implicated in cancer due to its ability to activate oncogenic intracellular signaling pathways in 
cancer cells and regulate immunosuppression in the tumor microenvironment [64,65]. 
IL-6 is a member of a family of cytokines that includes IL-11, IL-27, leukemia inhibitory 
factor (LIF), and oncostatin M (OSM), among others, all of which utilize the common signal 
transducing receptor glycoprotein 130 (gp130) [64,66–69]. The cytokines achieve specificity by 
binding not to gp130, but to unique cytokine receptors that subsequently dimerize with gp130 
[66,68,69]. 
IL-6 promotes activation of its receptor via two pathways, referred to as classic and trans-
signaling [67–69]. 
In classic IL-6 signaling, IL-6 binds to the membrane-bound IL-6 receptor-α (IL-6Rα), 
thus inducing formation of a heterohexameric complex consisting of two molecules each of IL-6, 
IL-6Rα, and gp130 [64,66]. Janus kinase (JAK) proteins bind to the Box1 and Box2 domains in 
the intracellular portion of gp130, leading to JAK-mediated phosphorylation of gp130 at several 
tyrosine residues, including four C-terminal residues that serve as docking sites for signal 
transducer and activator of transcription 3 (STAT3) [63,69]. Once bound to gp130, STAT3 is 
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phosphorylated by JAKs at tyrosine 705, leading to STAT3 dimerization and nuclear 
translocation, followed by STAT3-mediated transcription of target genes [65,69]. The IL-6/IL-
6Rα/gp130 complex can also activate the PI3K/Akt/mTOR and RAS/RAF/MEK/ERK pathways 
[67]. 
In IL-6 trans-signaling, soluble IL-6Rα (sIL-6Rα), rather than membrane-bound IL-6Rα, 
binds to IL-6. sIL-6Rα can be generated by alternative splicing of IL6R mRNA or, more often, 
by cleavage of membrane-bound IL-6Rα by disintegrin and metalloproteinase domain-containing 
protein 10 (ADAM10) or ADAM17 [65,67,68]. When IL-6 binds with sIL-6Rα, this complex is 
then able to bind to and induce the dimerization of membrane-bound gp130, leading to the 
activation of downstream signaling pathways (as described above for classic IL-6 signaling 
pathways) [65,67]. While gp130 is ubiquitously expressed, IL-6Rα is expressed in only a limited 
number of cell types [67,68]. Thus, trans-signaling via sIL-6Rα allows IL-6 to act on cells with 
limited or absent IL-6Rα expression. IL-6 trans-signaling can be negatively regulated by soluble 
gp130 (sgp130), which is generated by alternative splicing of IL6ST mRNA [67]. Soluble gp130 
competes with membrane-bound gp130 for binding to the IL-6–sIL-6Rα complex, thereby 
inhibiting IL-6 trans-signaling, but not the classic IL-6 signaling pathway [68]. 
As described in Chapter 1 and above, both EGFR and IL-6 promote activation of the 
JAK/STAT, PI3K/Akt/mTOR, and RAS/RAF/MEK/ERK pathways [67]. Thus, EGFR and IL-6 
signaling converge on several oncogenic signaling pathways, providing a plausible mechanism 
by which IL-6 could oppose the antitumor effects of cetuximab:  maintaining activation of these 
pathways in the context of EGFR inhibition. Indeed, previous investigations have demonstrated 
that downstream mediators of IL-6 signaling, particularly STAT3 and components of the 
PI3K/Akt pathway, can promote resistance to EGFR-targeted therapies [17,60,61]. 
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IL-6 itself was implicated in cetuximab resistance in a 2010 study focusing on pharyngeal 
cell lines [17]. In this study, cetuximab-resistant cells generated by treating parental (cetuximab-
sensitive) FaDu cells with increasing concentrations of cetuximab exhibited increased IL6 
expression and STAT3 phosphorylation compared to the parental cells from which they were 
derived [17]. The authors also showed that treating parental FaDu cells with cetuximab for 48 
hours reduced the number of viable cells in a dose-dependent manner, and that adding 
recombinant IL-6 tempered the effects of cetuximab on cell number [17]. In addition, in three 
pharyngeal cell lines (including FaDu), combining an IL-6 targeted monoclonal antibody with 
cetuximab more effectively reduced viable cell number than cetuximab alone (although it is 
unclear whether IL-6 inhibition alone had an impact, as these data were not reported) [17]. These 
data demonstrate that increased IL6 expression is correlated with cetuximab resistance in an 
HNSCC cell line and suggest that IL-6 inhibition may enhance cetuximab response [17]. 
Another study, published in 2013, provided further evidence that IL-6 may play a role in 
resistance to EGFR-targeted therapies in HNSCC [70]. In this study, IL-6 was among the pro-
inflammatory cytokines whose expression was increased upon treatment of HNSCC cell lines 
with the EGFR-targeted tyrosine kinase inhibitor erlotinib [70]. The authors found that treatment 
with recombinant IL-6 protected cells from erlotinib-induced cytotoxicity in clonogenic survival 
assays [70]. Moreover, treating mice bearing HNSCC cell line xenografts with a combination of 
erlotinib and the IL-6Rα-targeted monoclonal antibody tocilizumab further reduced tumor 
volume compared to treatment with erlotinib alone [70]. Notably, treatment with tocilizumab 
alone did not have a significant impact on tumor volume [70]. This study provided further 
evidence that IL-6 may play a role in resistance to EGFR inhibition in HNSCC. 
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These studies reporting that inhibition of the IL-6 pathway can enhance the antitumor 
effects of EGFR inhibitors suggest that IL-6 is not only a potential predictive biomarker of 
cetuximab resistance in HNSCC, but also a plausible therapeutic target, particularly in the 
context of cetuximab-resistant disease. Drugs targeting IL-6 and the IL-6 receptor, as well as 
downstream components of the IL-6 pathway, have been developed. Though none have been 
FDA approved for the treatment of HNSCC, some have been FDA approved for other 
indications [71–73]. Siltuximab, sirukumab, olokizumab, clazakizumab, and MEDI5117 are anti-
IL-6 monoclonal antibodies [65,74]. Tocilizumab and sarilumab are monoclonal antibodies that 
target IL-6Rα [65,67]. These antibodies inhibit both the classic and trans-signaling pathways 
[65,67]. In contrast, the gp130–Fc fusion protein olamkicept inhibits IL-6 trans-signaling but not 
the classic signaling pathway [65,67]. Tofacitinib, ruxolitinib, pacritinib, and AZD1480 are 
small-molecule tyrosine kinase inhibitors that target JAKs, preventing phosphorylation of 
STAT3 [65,75,76]. C188-9, OPB-31121, OPB-51602, and other Src homology domain 2 (SH2) 
domain inhibitors interfere with STAT3 dimerization [65]. The STAT3 antisense oligonucleotide 
AZD9150 binds to and causes the destruction of STAT3 mRNA, thus decreasing STAT3 
expression [65,77]. The cyclic STAT3 decoy contains a nucleotide sequence derived from the 
promoter of the STAT3 target gene FOS. This decoy competitively inhibits STAT3 binding to 
genomic response elements in the promoter regions of target genes [65,78]. Thus, there exist 
many therapeutic strategies to inhibit the IL-6 signaling if this pathway proves to be a therapeutic 
target in cetuximab-resistant HNSCC. 
Based on the results of the Phase II trial of cetuximab and dasatinib in HNSCC [48], as 
well as preclinical evidence supporting a role for IL-6 in cetuximab resistance, we investigated 
the role of the IL-6 pathway in preclinical HNSCC models of acquired cetuximab resistance. We 
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hypothesized that IL-6 would promote cetuximab resistance in HNSCC cells and that inhibiting 
the IL-6 pathway in a cell line model of acquired cetuximab resistance would restore sensitivity 
to cetuximab. Instead, we found that, despite increased IL-6 secretion in our cetuximab-resistant 
(CtxR) models, treatment of the parental (cetuximab-sensitive) cells with exogenous IL-6 did not 
promote cetuximab resistance, nor did inhibition of components of the IL-6 pathway restore 
cetuximab sensitivity in the CtxR cells. Further, we found that expression of IL6R, which encodes 
the IL-6 receptor subunit IL-6Rα, was substantially reduced in the CtxR cells compared to 
parental cells, and that CtxR cells did not respond to IL-6 stimulation with an increase in 
phosphorylation of STAT3 at Y705. Thus, though IL-6 secretion is correlated with cetuximab 
resistance in the PE/CA-PJ49 CtxR models, IL-6 is not required for the maintenance of 
cetuximab resistance in these cells, and targeting the IL-6 pathway may not restore cetuximab 
sensitivity even in cetuximab-resistant tumors that exhibit increased expression of this cytokine. 
 
2.2 Results 
IL-6 secretion is increased in cell line models of acquired cetuximab resistance. 
We recently reported the generation of cell line models of acquired cetuximab resistance 
derived from the parental HNSCC cell line PE/CA-PJ49 [56]. We reported that in these cell 
lines, an increase in expression of alternative receptor tyrosine kinases (RTKs), including AXL 
and MET, promotes resistance to EGFR inhibition. Expression of these alternative RTKs was 
driven by upregulation of the transcriptional co-activator bromodomain-containing protein-4 
(BRD4), and targeting BRD4 was able to restore cetuximab sensitivity in these cells [56]. 
Whether additional alterations in these model cell lines contribute to cetuximab resistance 
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remains unexplored. Thus, we utilized these models to assess the role of IL-6 in acquired 
resistance to cetuximab. 
We first confirmed that these PE/CA-PJ49 CtxR cells maintained resistance to cetuximab 
in 96-hour dose-response (Fig. 2.1A) and 12-day clonogenic survival (Fig. 2.1B) assays. Of 
note, PE/CA-PJ49 CtxR cells were also resistant to the EGFR-targeted tyrosine kinase inhibitor 
(TKI) erlotinib and the dual EGFR/HER2-targeted TKIs afatinib and lapatinib (Fig. 2.2), but 
remained sensitive to cisplatin and CBL0137, a novel anti-cancer agent targeting the facilitates 
chromatin transcription (FACT) complex [79,80] (Fig. 2.3), suggesting cross-resistance to EGFR 
targeting but not general treatment resistance. 
Previous studies focusing on mechanisms of resistance to cetuximab and other EGFR-
targeted therapies have demonstrated that EGFR inhibitor-resistant cells secrete increased levels 
of IL-6 compared to sensitive cells [17,61,81]. Consistent with these reports [17,61], IL6 mRNA 
expression was increased in the PE/CA-PJ49 cetuximab-resistant (CtxR) cells compared to the 
parental cells from which they were derived (Fig. 2.1C). To measure secreted IL-6 in our models 
of acquired cetuximab resistance, PE/CA-PJ49 parental and CtxR cells were plated in serum- and 
antibiotic-free media and an enzyme-linked immunosorbent assay (ELISA) was performed on 
cell culture supernatants collected after 72 hours. As shown in Fig. 2.1D, IL-6 was increased in 
the cell culture supernatants of CtxR cells compared to parental cells. These results suggested that 
IL-6 might play a role in acquired resistance to cetuximab in the PE/CA-PJ49 CtxR models and 
provided the impetus for further investigation of the IL-6 pathway. 
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Recombinant IL-6 does not confer cetuximab resistance in parental PE/CA-PJ49 cells. 
Because we observed an increase in IL-6 secretion in the cetuximab-resistant PE/CA-
PJ49 cells compared to parental cells, and because IL-6 and its downstream effector STAT3 have 
been previously implicated in cetuximab resistance [17,61], we sought to determine whether 
addition of recombinant human IL-6 (rhIL6) would abrogate the growth inhibitory effects of 
cetuximab in PE/CA-PJ49 parental cells. 
Before testing the impact of rhIL6 addition on cetuximab response in the PE/CA-PJ49 
parental cells, we first determined whether rhIL6 was able to activate signaling downstream of 
the IL-6 receptor. The media on PE/CA-PJ49 parental cells was replaced with DMEM (no FBS) 
or DMEM supplemented with 10% FBS. After 4 hours, the cells were treated with 50 ng/mL 
rhIL6 for 15 minutes or 4 hours. Phosphorylation of STAT3 at tyrosine 705 (P-STAT3Y705) was 
increased upon addition of rhIL6 in both the no FBS and 10% FBS conditions, while total 
STAT3 levels remained stable (Fig. 2.4A), demonstrating that rhIL6 can indeed activate the 
JAK/STAT pathway in these cells even in the presence of serum. To assess the impact of rhIL6 
on cetuximab response, we treated the cells for 96 hours with 100 nM Ctx, 50 ng/mL rhIL6, or 
the combination of Ctx and rhIL6, then stained the cells with crystal violet (Fig. 2.4B). The 
addition of rhIL6 did not prevent cetuximab-induced growth inhibition in the PE/CA-PJ49 
parental cells (Fig. 2.4B,C). These findings indicate that exogenous IL-6 alone cannot promote 
cetuximab resistance in this model cell line. 
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Inhibition of the IL-6 pathway does not impact cetuximab response in PE/CA-PJ49 
parental and CtxR cells. 
 Although addition of recombinant IL-6 did not promote cetuximab resistance in PE/CA-
PJ49 parental cells, this did not rule out the possibility that IL-6 played a role in the maintenance 
of cetuximab resistance in the CtxR cell lines. This was an appealing prospect because if IL-6 
were required to maintain cetuximab resistance, then targeting the IL-6 pathway could be used to 
restore cetuximab sensitivity in these cell lines, and, potentially, in cetuximab-resistant HNSCC 
tumors. To determine whether inhibiting the IL-6 pathway could restore cetuximab sensitivity in 
the PE/CA-PJ49 CtxR cell lines, we used both genetic and pharmacologic approaches to inhibit 
components of the IL-6 pathway alone and in combination with cetuximab. 
To determine the impact of IL6 knockdown on cetuximab response, we first confirmed 
that the siRNAs targeting IL6 reduced IL6 mRNA expression by transfecting PE/CA-PJ49 
parental cells with 10 nM nontargeting (nt) siRNA or one of two distinct IL6-targeted siRNAs 
(siIL6 A and B). After 96 hours, quantitative reverse transcription PCR (qPCR) was performed 
to assess IL6 mRNA levels. Cells transfected with either siIL6 A or siIL6 B exhibited a 
substantial reduction in IL6 mRNA levels compared to nt-transfected cells (Fig. 2.5A). 
We next plated PE/CA-PJ49 parental and CtxR cells at a low density to conduct 
clonogenic survival assays. Cells were transfected with 10 nM nt siRNA, siIL6 A, or siIL6 B and 
treated the next day (and every four days thereafter) with vehicle (PBS) or 100 nM Ctx. After 12 
days of treatment (13 days post-transfection), the colonies were stained with crystal violet. As 
expected, PE/CA-PJ49 parental cells were sensitive to cetuximab (Fig. 2.5B). Transfection with 
siIL6 itself reduced the number of colonies per well in the parental and CtxR cells, and the 
combination of cetuximab and siIL6 had an additive effect in parental cells. However, siIL6-
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transfected CtxR cells treated with vehicle and cetuximab were indistinguishable, demonstrating 
that the CtxR cells remain resistant to cetuximab even when IL6 expression is greatly reduced. 
Next, we examined the impact of knocking down other components of the IL-6 pathway 
on cetuximab response. IL-6 signals through a receptor complex consisting of interleukin-6 
receptor alpha (IL-6Rα, encoded by IL6R) and glycoprotein 130 (gp130, encoded by IL6ST). IL-
6 signaling is initiated when IL-6 binds to IL-6Rα and the IL-6/IL-6Rα complex binds to gp130. 
Subsequent dimerization of gp130 leads to the formation of a heterohexameric signaling 
complex that recruits JAK proteins, leading to phosphorylation and nuclear localization of 
STAT3 [73,82–85]. Both IL-6Rα and gp130, in addition to IL-6, are required to initiate IL-6 
signaling [73,83,84]; thus, if IL-6 signaling is required to maintain cetuximab resistance in the 
PE/CA-PJ49 CtxR cells, inhibition of either co-receptor would be expected to restore cetuximab 
sensitivity in these cells. Transfection of PE/CA-PJ49 parental cells with siIL6R (Fig. 2.6) or 
siIL6ST (Fig. 2.7) substantially reduced the mRNA levels of their respective targets in PE/CA-
PJ49 parental cells. However, as observed when IL6 was knocked down, neither siIL6R nor 
siIL6ST restored cetuximab sensitivity in the CtxR cell lines (Fig. 2.6 and 2.7). 
To corroborate the results we obtained using siRNAs with a more clinically relevant 
agent, we used tocilizumab (TCZ), an IL-6Rα-targeted monoclonal antibody that is FDA 
approved for the treatment of rheumatoid arthritis and chimeric antigen receptor (CAR) T cell-
induced cytokine release syndrome. To select a concentration of TCZ for use in subsequent 
experiments, we serum starved PE/CA-PJ49 parental cells for 2 hours, then pre-treated the cells 
with vehicle (PBS) or increasing concentrations of TCZ for 2 hours before treating the cells for 
15 minutes with 50 ng/mL rhIL6. We found that 100 nM TCZ was sufficient to block rhIL6-
induced STAT3 phosphorylation (Fig. 2.8A) and selected 1 μM TCZ as the concentration for 
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subsequent experiments because a further decrease in STAT3 phosphorylation was observed in 
cells treated with this concentration. 
To assess the impact of TCZ on cetuximab response in the PE/CA-PJ49 parental and 
CtxR cells, we again plated the cells at a low density, then treated the cells with vehicle (PBS), 
100 nM Ctx, 1 μM TCZ, or the combination of Ctx and TCZ, replacing media plus drug(s) every 
four days, for a total of 12 days of treatment (Fig. 2.8B,C). In cells treated with cetuximab alone, 
a substantial decrease in crystal violet-stained material was observed in PE/CA-PJ49 parental 
cells, but not CtxR cells. Treatment with TCZ, whether alone or in combination with cetuximab, 
did not have an impact on colony formation in parental or CtxR cells (Fig. 2.8B,C). 
Despite a substantial increase in IL-6 levels (both mRNA expression and secreted 
cytokine) in the CtxR cell lines compared to PE/CA-PJ49 parental cells, inhibition of components 
of the IL-6 pathway using both genetic (siRNA) and pharmacological (TCZ) methods did not 
impact cetuximab response in the CtxR cells. Together, these results suggest that IL-6 signaling is 
not required for maintenance of cetuximab resistance in these models. 
 
Expression of components of the IL-6 pathway are altered in HNSCC cells that have 
acquired resistance to cetuximab. 
Though IL-6 levels are increased in PE/CA-PJ49 CtxR cells compared to parental cells 
(Fig. 2.1), treatment of parental cells with rhIL6 did not promote cetuximab resistance (Fig. 2.4), 
and inhibition of the IL-6 pathway failed to reverse cetuximab resistance in the CtxR cells (Fig. 
2.5-2.8). Seeking an explanation for this discrepancy, we analyzed expression of gp130 and IL-
6Rα, both of which are required for IL-6 signal transduction, in parental and CtxR PE/CA-PJ49 
cells. 
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Expression of gp130 (encoded by the IL6ST gene) was evaluated by qPCR and 
immunoblot analysis and found to be increased at both the mRNA (Fig. 2.9A) and protein (Fig. 
2.9C,D) levels in CtxR cells compared to parental PE/CA-PJ49 cells. In contrast, mRNA 
expression of IL6R (the gene encoding IL-6Rα) was decreased in PE/CA-PJ49 CtxR cells 
compared to parental cells (Fig. 2.9B). This raises the question of whether IL-6 signaling is 
functionally intact in the PE/CA-PJ49 CtxR cells. 
 
IL-6 signaling is impaired in PE/CA-PJ49 CtxR cells. 
Although both IL-6 and gp130 levels were increased in CtxR PE/CA-PJ49 cells, IL-6Rα 
levels were decreased in these cells compared to parental cells, revealing a disconnect among the 
components of the IL-6 signaling pathway. This discrepancy led us to examine the net impact of 
these alterations on downstream components of the IL-6 signaling pathway in the PE/CA-PJ49 
CtxR cells. 
We compared P-STAT3Y705 levels in PE/CA-PJ49 parental and CtxR cells and found that 
the ratio of P-STAT3Y705 to total STAT3 was decreased in CtxR cells compared to parental cells 
(Fig. 2.10A,B), consistent with impaired IL-6 signaling in the CtxR cells. However, because 
STAT3 phosphorylation is dynamically regulated by a number of kinases and phosphatases, the 
decrease in P-STAT3Y705 in the CtxR cells alone does not conclusively demonstrate a defect in 
IL-6 signaling. Thus, we assessed IL-6 signaling more directly by serum starving parental and 
CtxR PE/CA-PJ49 cells, then treating the cells for 15 minutes with 50 ng/mL rhIL6. Consistent 
with our findings in Fig. 2.4A, addition of rhIL6 stimulated phosphorylation of STAT3 at Y705 
in the parental cells. However, no increase in P-STAT3Y705 was observed following 15 minutes 
of rhIL6 treatment in any of the CtxR lines (Fig. 2.10C and 2.11). 
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To determine whether this defect was IL-6-specific, we tested whether P-STAT3Y705 
levels in the CtxR cells were increased following treatment with recombinant human leukemia 
inhibitory factor (rhLIF) or recombinant human oncostatin M (rhOSM). LIF and OSM are IL-6 
family cytokines that utilize gp130 for signal transduction, but bind to non-IL-6Rα co-receptors 
to initiate signaling [83]. We serum starved PE/CA-PJ49 parental and CtxR cells for 4 hours, then 
treated the cells for 15 minutes with 50 ng/mL rhIL6 or rhLIF. While rhLIF treatment induced 
STAT3 phosphorylation at Y705 in the parental and CtxR cell lines, rhIL6 increased P-
STAT3Y705 levels in only the parental cells (Fig. 2.10C). Similar results were observed when 
cells were treated with rhOSM:  Serum-starved parental and CtxR cell lines all responded to 
rhOSM treatment with an increase in P-STAT3Y705 (Fig. 2.11). 
PE/CA-PJ49 parental and CtxR cell lines all responded to treatment with the IL-6 family 
cytokines LIF and OSM with an increase in P-STAT3Y705, demonstrating that gp130 and 
JAK/STAT3 signaling are functionally competent in these cells. In contrast, only the parental 
cells responded to treatment with rhIL6, suggesting that the decreased IL6R expression in the 
PE/CA-PJ49 CtxR cells impacted their ability to mediate IL-6 signaling and providing further 
evidence that IL-6 is not required for the maintenance of cetuximab resistance in these cells. 
 
2.3 Discussion 
Based on evidence in preclinical models and the finding that serum IL-6 was a biomarker 
of resistance to cetuximab-containing therapy in a Phase II trial [48], we initially hypothesized 
that IL-6 mediated cetuximab resistance in HNSCC cells and that targeting the IL-6 pathway 
could overcome cetuximab resistance. Our initial characterization of IL6 expression and 
secretion in the PE/CA-PJ49 CtxR cells was consistent with a role for IL-6 in cetuximab 
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resistance, as IL-6 levels were increased in all three CtxR models compared to the parental 
PE/CA-PJ49 cells from which they were derived. However, inhibition of the IL-6 pathway did 
not restore cetuximab sensitivity in the CtxR models, and subsequent analyses revealed that, 
though parental PE/CA-PJ49 cells responded to IL-6 treatment with an increase in P-STAT3Y705, 
the CtxR cells failed to do so, possibly due to the substantial decrease in expression of IL6R in 
the CtxR cells. These cumulative results suggest that, despite an increase in IL-6 secretion in the 
PE/CA-PJ49 CtxR models, IL-6 does not mediate cetuximab resistance in these models. 
This project was initiated based on the results of a Phase II clinical trial performed to 
identify potential predictive biomarkers of response to a combination of cetuximab and dasatinib 
in HNSCC patients whose tumors had previously progressed on cetuximab-containing therapy 
[48]. The investigators found that, out of four candidate serum biomarkers, only IL-6 serum 
levels were shown to be correlated with resistance to the combination of cetuximab and dasatinib 
[48]. This clinical trial, along with the aforementioned preclinical studies linking IL-6 with 
resistance to EGFR inhibitors in HNSCC cells [17,70], suggested that IL-6 could be a predictive 
biomarker of resistance to cetuximab. However, there exists a crucial difference between our 
study and the clinical trial on which this project was based:  While our study focused on 
cetuximab resistance, the clinical trial focused on the association of IL-6 with resistance to a 
combination of cetuximab and dasatinib. Taken together, these results suggest that IL-6 might 
promote resistance to the combination of cetuximab and dasatinib, or to dasatinib alone, but not 
to cetuximab alone. Further experiments in additional models would be needed to test this. 
 With regards to the papers by Chen et al. and Fletcher et al., which demonstrated that 
inhibition of IL-6 signaling could enhance the anti-tumor effects of EGFR inhibitors alone 
[17,70], any number of factors could explain the discrepancies in our findings – for example, the 
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findings could simply be cell line-specific. An additional consideration is that, while we focused 
on the effects of IL-6 inhibition in cells that had already acquired resistance to cetuximab, the 
cited papers treated EGFR inhibitor-naïve cells with IL-6 inhibitors. Thus, our disparate findings 
might simply reflect differences in the role of IL-6 upon initial treatment with EGFR inhibitors 
and after months of treatment with increasing concentrations of the drug. Though we concluded 
that IL-6 is not required for the maintenance of cetuximab resistance in the PE/CA-PJ49 CtxR 
cells, IL-6 could have played a role in the acquisition of cetuximab resistance. It has previously 
been shown that erlotinib-induced NF-κB-mediated IL6 expression promotes survival of non-
small cell lung cancer cells treated with this EGFR tyrosine kinase inhibitor, and it was 
suggested that this adaptive response to erlotinib treatment could ultimately promote acquired 
resistance to this drug [86]. We observed an increase in IL6 mRNA expression when parental 
PE/CA-PJ49 cells were treated with cetuximab for 96 hours (Fig. 2.12), suggesting that IL6 
expression is increased in response to cetuximab treatment and that the increase in IL-6 secretion 
occurs prior to the acquisition of cetuximab resistance in the PE/CA-PJ49 cells. This finding is 
consistent with the erlotinib-induced increase in IL-6 reported by Fletcher et al. [70]. Given the 
previously demonstrated role of IL-6 in promoting cell survival upon treatment with EGFR 
inhibitors [86], future studies may test the hypothesis that cetuximab-induced secretion of IL-6 
allows cetuximab-sensitive cells to persist during treatment, enabling the eventual acquisition of 
resistance by persister cells. 
Our conclusion that IL-6 does not promote cetuximab resistance in the PE/CA-PJ49 CtxR 
cells despite an upregulation in IL6 expression, though initially surprising, is not without 
precedent. A previous study found that, despite increased secretion of IL-6 in HNSCC cell line 
models of acquired resistance to cisplatin, IL-6 did not mediate cisplatin resistance in these cells 
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[87]. Moreover, expression of IL6R was decreased in the cisplatin-resistant cells, and the authors 
speculated that this decrease in IL6R expression impaired IL-6 signaling [87]. Thus, in both 
cetuximab-resistant and cisplatin-resistant HNSCC cells, an increase in IL-6 secretion in 
conjunction with the emergence of drug resistant cells does not necessarily demonstrate that IL-6 
is required for maintenance of drug resistance. It also raises the intriguing question of why IL6R 
expression was decreased in both of these drug resistance models. Was IL6R simply a bystander 
lost during acquisition of drug resistance, or were the decreases in IL6R expression due to 
selective pressure? Examination of these and other possibilities could be addressed in future 
studies. We emphasize that our conclusion that IL-6 is not required for the maintenance of 
cetuximab resistance is specific to the PE/CA-PJ49 models used in this study. IL-6 may be 
involved in the maintenance of acquired resistance in IL-6 signaling-competent cells – indeed, 
this may explain a discrepancy between our findings and those of Chen et al. [17]. We predict 
that IL-6 may be dispensable for the maintenance of cetuximab resistance in other cells in which 
IL6R expression is decreased or absent, or in which IL-6 signaling is otherwise impaired. This 
prediction may be tested in the future. 
The inability of the PE/CA-PJ49 CtxR cells to activate STAT3 in response to treatment 
with recombinant IL-6 suggests that the decrease in IL6R expression had a functional impact on 
response to IL-6.  Because both IL-6Rα and gp130 are required to form functional IL-6 
receptors, it is perhaps not surprising that the substantial reduction in IL-6Rα levels in PE/CA-
PJ49 CtxR cells would impede the ability of IL-6 to induce STAT3 phosphorylation (Fig 5C; S6 
Fig). In light of these findings, the inability of IL-6 pathway inhibition to reverse cetuximab 
resistance in the CtxR cells is not surprising; indeed, the results would have been difficult to 
interpret had IL-6 inhibition restored cetuximab sensitivity in cells in which IL-6 signaling is 
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impaired. However, though we hypothesize that the impairment in IL-6 signaling is due the 
decrease in IL6R expression, it could be due to other alterations in the CtxR cells. Additional 
experiments would need to be conducted to conclude that the decrease in IL-6Rα levels was 
responsible for the functional impairment in IL-6 signaling in CtxR cells. For example, if 
overexpressing IL-6Rα restored the ability of the CtxR cells to phosphorylate STAT3 in response 
to treatment with IL-6, this would suggest that the impairment in IL-6 signaling was indeed due 
to the decrease in IL6R expression. Moreover, the inability of recombinant IL-6 to activate IL-6 
signaling in the CtxR cells does not rule out the possibility that IL-6 signals intracellularly, as IL-
6 has been shown to activate signaling within endosomes [88]. This may explain an apparent 
discrepancy in Fig. 2.5, 2.6, and 2.8, in which siRNA-mediated knockdown of IL6 or IL6R, but 
not treatment with the IL-6Rα-targeted agent TCZ, reduces colony number in PE/CA-PJ49 
parental and CtxR cells. Though this does not appear to play a role in the maintenance of 
cetuximab resistance, since knockdown of IL6, IL6R, and IL6ST did not sensitize the cells to 
cetuximab, the respective contributions of intracellular and extracellular IL-6 in HNSCC may be 
a topic of further study. 
Notably, our results also do not rule out a potential role for IL-6 in cetuximab resistance 
in an in vivo setting. PE/CA-PJ49 cells do not reliably form xenograft tumors in even the 
severely immunocompromised NOD scid gamma strain of mice, so the experiments described 
above were conducted exclusively in cell culture or in samples derived from cell lines. These 
isolated cell culture models lack 3D architecture and components of the tumor 
microenvironment, including immune cells, which are especially relevant in the context of 
cetuximab treatment because one of cetuximab’s mechanisms of action is immune cell-
dependent. Cetuximab is a monoclonal antibody and has been shown to mediate ADCC, a 
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phenomenon in which immune cells (primarily natural killer cells) recognize and kill cells 
opsonized by antibodies [15]; thus, impairment of this process could impede the ability of 
cetuximab to promote immune-mediated tumor cell destruction. An abundance of evidence has 
established that IL-6 plays many roles in the tumor microenvironment, often as an 
immunosuppressive cytokine [89,90], and it is tempting to speculate that IL-6 secretion by 
cetuximab-resistant tumor cells could promote cetuximab resistance by downregulating 
cetuximab-induced ADCC. Future studies may explore whether IL-6 plays a role in resistance to 
cetuximab-induced ADCC, perhaps in a tumor/immune cell co-culture model. 
IL-6 upregulation has been repeatedly demonstrated in the context of treatment with, and 
resistance to, cetuximab and other EGFR-targeted therapies [17,48,70,86]. Upon observation that 
IL-6 secretion was increased in PE/CA-PJ49 CtxR cells compared to parental cells, we expected 
to find that IL-6 mediated cetuximab resistance and that inhibiting the IL-6 pathway would 
restore cetuximab sensitivity in CtxR cells. Instead, we found that the increase in IL-6 secretion 
by PE/CA-PJ49 CtxR cells belied a functional impairment in the IL-6 signaling pathway. These 
findings demonstrate that, even when IL-6 levels are increased in the context of cetuximab 
resistance, this does not necessarily indicate that IL-6 mediates cetuximab resistance. This study 
highlights the importance of differentiating between alterations that are simply correlated with 
cetuximab resistance and those that play a functional role in maintaining cetuximab resistance in 
order to identify promising candidates to target to overcome cetuximab resistance. 
 
 
 
 
27 
 
2.4 Figures 
 
 
Figure 2.1. Cell line models of acquired cetuximab resistance exhibit increased IL-6 
secretion. A) PE/CA-PJ49 parental and CtxR cells were treated for 96 h with vehicle (PBS) or 
cetuximab (0.1 nM – 1 μM), then stained with crystal violet. Student’s two-tailed t-test was used 
to determine whether differences in absorbance at 590 nm were statistically significant 
(compared to vehicle-treated cells). n=4. B) Cells were plated at low density and treated the next 
day with vehicle (PBS) or 100 nM cetuximab. Cells were stained with crystal violet after 12 days 
of cetuximab treatment. Media containing vehicle or cetuximab was changed every 4 days. C) 
RNA was extracted from PE/CA-PJ49 parental and CtxR cells and qPCR was conducted using 
the IL6 primers listed in Table 4.1 (normalized to TBP). n=3. D) PE/CA-PJ49 parental cells and 
CtxR cells were plated in serum-free medium. Conditioned medium was collected after 72h and 
concentration of IL-6 was measured using ELISA. Student’s two-tailed t-test was used to 
determine whether differences in IL6 expression and secreted IL-6 were statistically significant 
(compared to parental cells). n=4. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; n.s., not 
significant. 
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Figure 2.2. Cetuximab-resistant PE/CA-PJ49 cells are cross-resistant to EGFR-targeted 
TKIs. A,B,C) Erlotinib (A), afatinib (B), and lapatinib (C) dose response assays in PE/CA-PJ49 
parental cells and CtxR clones treated for 96 h, then stained with crystal violet. n=6. D) PE/CA-
PJ49 parental cells and CtxR clones were plated at low density and treated with vehicle (DMSO), 
100 nM erlotinib, 1 nM afatinib, or 1 μM lapatinib, then stained with crystal violet after 12 days 
of treatment. Media containing vehicle or drug was changed every four days. n=4. 
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Figure 2.3. Cetuximab-resistant PE/CA-PJ49 cells are not resistant to cisplatin and 
CBL0137. A,B) Cisplatin (A) and CBL0137 (B) dose response assays in PE/CA-PJ49 parental 
and CtxR cells treated for 96 h, then stained with crystal violet. n=6. 
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Figure 2.4. Addition of recombinant IL-6 does not promote cetuximab resistance in PE/CA-
PJ49 parental cells. A) PE/CA-PJ49 parental cells were serum starved for 4 hours (no FBS) or 
remained in media containing 10% FBS (10% FBS), then treated with 50 ng/mL rhIL6 for 15 
min or 4 hours. Cells were lysed in RIPA buffer and immunoblot was performed as described in 
Materials and Methods. β-tubulin image shown is from the STAT3 blot. B) PE/CA-PJ49 parental 
cells were treated for 96 h with vehicle (PBS), 50 ng/mL rhIL6, 100 nM Ctx, or the combination 
of Ctx and rhIL6, then stained with crystal violet. Images shown are representative of three 
biological replicates. C) Quantification of crystal violet staining in Fig. 2B. Student’s two-tailed 
t-test was used to determine whether differences in absorbance at 590 nm were statistically 
significant (compared to vehicle-treated cells). n=3. **p<0.01; n.s., not significant. 
 
31 
 
 
Figure 2.5. siRNA-mediated knockdown of IL6 does not impact cetuximab response in 
PE/CA-PJ49 parental and CtxR cells. A) PE/CA-PJ49 parental cells were transfected with 10 
nM nontargeting (nt) siRNA or one of two siRNAs targeting IL6 (siIL6 A and B). RNA was 
extracted 96 hours post-transfection and qPCR was conducted using the IL6 primers listed in 
Table 4.1 (normalized to TBP). n=3. *p<0.05. B) PE/CA-PJ49 parental and CtxR cells were 
plated at a low density and transfected with 10 nM siRNA the next day. On the following day, 
and every four days thereafter, the cells were treated with vehicle (PBS) or 100 nM Ctx. The 
cells were stained with crystal violet 13 days post-transfection. 
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Figure 2.6. siRNA-mediated knockdown of IL6R does not impact cetuximab response in 
PE/CA-PJ49 parental and CtxR cells. A) PE/CA-PJ49 parental cells were transfected with 10 
nM nontargeting (nt) siRNA or one of two siRNAs targeting IL6R (siIL6R A and C). RNA was 
extracted 96 hours post-transfection and qPCR was conducted using the IL6R primers listed in 
Table 4.1 (normalized to TBP). n=3. **p<0.01. B) PE/CA-PJ49 parental and CtxR cells were 
plated at a low density and transfected with 10 nM siRNA the next day. On the following day, 
and every four days thereafter, the cells were treated with vehicle (PBS) or 100 nM Ctx. The 
cells were stained with crystal violet 13 days post-transfection. 
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Figure 2.7. siRNA-mediated knockdown of IL6ST does not impact cetuximab response in 
PE/CA-PJ49 parental and CtxR cells. A) PE/CA-PJ49 parental cells were transfected with 10 
nM nontargeting (nt) siRNA or one of three siRNAs targeting IL6ST (siIL6ST A, B, and C). 
RNA was extracted 96 hours post-transfection and qPCR was conducted using the IL6ST primers 
listed in Table 4.1 (normalized to TBP). n=3. ****p<0.0001. B) PE/CA-PJ49 parental and CtxR 
cells were plated at a low density and transfected with 10 nM siRNA the next day. On the 
following day, and every four days thereafter, the cells were treated with vehicle (PBS) or 100 
nM Ctx. The cells were stained with crystal violet 13 days post-transfection. 
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Figure 2.8. Pharmacological inhibition of the IL-6 pathway does not impact cetuximab 
response in PE/CA-PJ49 parental and CtxR cells. A) Serum-starved PE/CA-PJ49 parental 
cells were pre-treated for 2 hours with vehicle (PBS) or 100 nm – 5 μM TCZ, then treated with 
50 ng/mL rhIL6 for 15 minutes. Cells were lysed in RIPA buffer and immunoblot was 
performed. β-tubulin image shown is from the STAT3 blot. B) PE/CA-PJ49 parental and CtxR 
cells were plated at a low density, then treated with vehicle (PBS), 100 nM Ctx, 1 μM TCZ, or 
the combination of Ctx and TCZ every 4 days. After a total of 12 days of treatment, the cells 
were stained with crystal violet. C) Crystal violet-stained cells from (B) were solubilized and 
absorbance at 590 nm was measured. Student’s two-tailed t-test was used to determine whether 
differences in absorbance at 590 nm were statistically significant (compared to vehicle-treated 
cells). n=3. *p<0.05; **p<0.01. 
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Figure 2.9. Expression of components of the IL-6 pathway are altered in HNSCC cells that 
have acquired resistance to cetuximab. A,B) RNA was extracted from PE/CA-PJ49 parental 
cells and cetuximab-resistant clones and qPCR was conducted using the IL6ST (A) or IL6R (B) 
primers listed in Table 4.1 (normalized to TBP). n=3. C) Cells were lysed in RIPA buffer and 
immunoblot was performed. Images depicted are representative of three biological replicates. D) 
Densitometry was performed on the blots depicted in (C) using ImageJ as described in Materials 
and Methods. Densitometry values for gp130 were normalized to those for the loading control 
(β-tubulin). Student’s t-test was used to determine whether differences in the gp130/β-tubulin 
ratios in CtxR cells were statistically significant compared to parental cells. n=3. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
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Figure 2.10. IL-6 signaling is impaired in PE/CA-PJ49 CtxR cells. A) PE/CA-PJ49 parental 
and CtxR cells were lysed in RIPA buffer and immunoblot was performed. Images shown are 
representative of three biological replicates. β-tubulin image shown is from the STAT3 blot. B) 
Densitometry was performed using ImageJ as described in Materials and Methods. Densitometry 
values for P-STAT3Y705 were normalized to those for total STAT3. Student’s t-test was used to 
determine whether differences in the P-STAT3Y705:STAT3 ratios in CtxR cells were statistically 
significant compared to parental cells. n=3. *p<0.05; **p<0.01. C) PE/CA-PJ49 parental and 
CtxR cells were serum starved for 4 hours, then treated for 15 minutes with 50 ng/mL rhIL6 or 
rhLIF. Cells were lysed in RIPA buffer and immunoblot was performed. β-tubulin image shown 
is from the P-STAT3Y705 blot. 
 
 
Figure 2.11. Phosphorylation of STAT3 is induced in PE/CA-PJ49 CtxR cells treated with 
rhOSM, but not rhIL6. PE/CA-PJ49 parental and CtxR cells were serum starved for 4 hours, 
then treated for 15 minutes with 50 ng/mL rhIL6 or rhOSM. Cells were lysed in RIPA buffer and 
immunoblot was performed. 
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Figure 2.12. IL6 mRNA expression is increased in Ctx-treated PE/CA-PJ49 parental cells. 
PE/CA-PJ49 parental cells were treated with vehicle (PBS) or 100 nM Ctx. After 96 hours of 
treatment, RNA was extracted and qPCR was conducted using the IL6 primers listed in Table 
4.1 (normalized to TBP). Student’s two-tailed t-test was used to determine whether differences in 
IL6 expression were statistically significant. n=3. **p<0.01. 
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Chapter 3:  Targeted sequencing analysis of cetuximab-sensitive and 
cetuximab-resistant variants of an HNSCC cell line 
3.1 Introduction 
Thus far, hypothesis-driven approaches to identify targetable mechanisms of resistance to 
cetuximab, including our own study on the role of IL-6 in cetuximab resistance, have not yielded 
any clinically validated therapeutic strategies to overcome cetuximab resistance in HNSCC. 
Alternative strategies may yield new insights into the biology of cetuximab resistance and 
expand the list of potential therapeutic targets in cetuximab-resistant HNSCC. 
To glean more information from the cetuximab-resistant PE/CA-PJ49 cells, we used an 
unbiased approach, next-generation DNA sequencing using a targeted gene panel (UCSF500 
Cancer Gene Panel) [91], to identify potential mediators of cetuximab resistance in these cells. In 
this panel, approximately 500 cancer-associated genes are sequenced, revealing single nucleotide 
variants (SNVs), insertions/deletions (indels), and copy number changes, as well as 
rearrangements that are commonly observed in cancer. This unbiased analysis could reveal novel 
genetic alterations correlated with acquired cetuximab resistance and inform future studies aimed 
at determining whether these alterations promote cetuximab resistance. 
 
3.2 UCSF500 analysis in parental and cetuximab-resistant PE/CA-PJ49 cells 
Genomic DNA isolated from the PE/CA-PJ49 parental and CtxR cells was sent to the 
UCSF Clinical Cancer Genomics Laboratory for sequencing. The data generated from the 
analysis were filtered as described in the Materials and Methods (Chapter 4) and used to 
compare the PE/CA-PJ49 parental and CtxR cells. Many of the SNVs and indels were shared 
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among the parental and CtxR cells (Table 3.1), providing further evidence (along with short 
tandem repeat analysis) that the CtxR cells are indeed PE/CA-PJ49 variants. The parental cells 
harbored more unique SNVs and indels than any of the three CtxR cell lines, but each cell line 
bore mutations that were not observed in the other three lines, suggesting heterogeneity among 
the clones (Table 3.2). Likewise, many of the copy number changes, including TERT and 
PLAG1 amplifications, were shared among the cell lines (Supplementary Table 1). 
Notably, the analysis did not uncover any alterations in EGFR in the parental or the CtxR 
cells, suggesting that alteration of the gene that encodes the protein targeted by cetuximab is not 
what mediates cetuximab resistance in these cells. In addition, although we observed increased 
gp130 levels in the CtxR cells, no alterations in the IL6ST gene were identified in the analysis 
(IL6 and IL6R are not among the genes sequenced on this platform). A region on chromosome 17 
that contains the STAT3 gene appeared to be amplified in only the CtxR 1 and CtxR 4 in the 
filtered data, but reviewing the unfiltered data reveals that the parental and CtxR 3 cells also 
contain the chromosome 17 amplification, but with fold changes of 2 that fall below the cutoff of 
2.5. This is in line with the observation that there is no increase in STAT3 protein expression in 
the CtxR cells compared to the parental cells (Fig. 2.8). 
 
3.3 Unique mutations identified in cetuximab-resistant PE/CA-PJ49 cells 
Targeted sequencing of our models identified a number of unique mutations in each of 
the four cell lines tested. The PE/CA-PJ49 parental cells contained more unique SNVs and indels 
than any of the CtxR cell lines, perhaps because each CtxR cell line was derived from a single 
clone of cetuximab-treated parental cells. However, each of the CtxR cells also harbored unique 
mutations. Their absence in the parental cells suggests that these mutations arose de novo 
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following the initiation of cetuximab treatment, but it remains possible that these mutations 
existed in the pool of PE/CA-PJ49 parental cells from which the CtxR cells were derived, but 
were not present in a sufficient fraction of the parental cells to be detectable in our targeted 
sequencing analysis. Notably, none of the mutations unique to the CtxR cells were shared among 
the three CtxR lines (Table 3.2). 
Whether the unique mutations in the CtxR cells are simply correlated with or indeed 
promote cetuximab resistance remains unknown and will require additional experiments. 
However, given previously published information on the functions of the proteins encoded by 
these genes, we can speculate on the potential roles of these mutations in cetuximab resistance. 
 
PE/CA-PJ49 CtxR 1 
Both of the genes that were altered in only the PE/CA-PJ49 CtxR 1 cells, KAT6A and 
NSD1 (Table 3.2), are involved in epigenetic regulation of gene expression. 
KAT6A encodes lysine acetyltransferase 6A (KAT6A), a histone acetyltransferase 
[92,93]. The specific alteration identified in this analysis (p.1228_1228del) has not been 
reported; thus, its impact on KAT6A protein expression and function are unknown. However, the 
mutation occurs in the acidic domain of the protein, and nearby frameshift mutations affecting 
this region of the protein have been implicated as pathogenic variants in KAT6A syndrome, a 
rare neurodevelopmental disorder [93]. Notably, however, this mutation is a nonframeshift 
deletion, and may not have the deleterious effect that frameshift mutations in this region have. 
On the other hand, KAT6A mRNA levels are increased in glioblastoma samples compared to 
normal brain tissue, and KAT6A and has been shown to promote glioma cell proliferation via 
upregulation of PIK3CA expression and subsequent activation of PI3K/Akt signaling [92]. Thus, 
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if the mutation identified in the CtxR 1 cells is an activating mutation, this KAT6A alteration 
could promote cetuximab resistance by activating PI3K/Akt signaling, a previously identified 
mediator of cetuximab resistance [5,18,52,60]. 
NSD1 encodes nuclear receptor binding SET domain protein 1 (NSD1), a histone 
methyltransferase [2,10,94]. The NSD1 mutation identified in the CtxR 1 cells, p.G1132fs, has 
not been previously reported. However, novel inactivating mutations in NSD1 were identified in 
29 of the 279 HNSCC tumors in the TCGA published in 2015 (all in HPV-negative tumors) [10], 
and the constellation of non-hotspot mutations suggest that this mutation, too, may be 
inactivating, potentially resulting in DNA hypomethylation. NSD1 inhibition has been shown to 
enhance sensitivity to cisplatin and carboplatin in head and neck cancer cell lines [2,94], but the 
impact of loss-of-function mutations in NSD1 on cetuximab response is unknown. Notably, 
alterations in DNA methylation patterns have been associated with acquired resistance to 
cetuximab [95]. This will be discussed more in Section 3.4. 
 
PE/CA-PJ49 CtxR 3 
PE/CA-PJ49 CtxR 3 cells, but not the other PE/CA-PJ49 clones analyzed, contain a 
nonsynonymous mutation (p.D774E) in CHD5, the gene encoding the tumor suppressor 
chromodomain helicase DNA binding protein 5 (CHD5) [96] and a frameshift substitution 
(c.864delinsCC) in HNF1A, which encodes hepatocyte nuclear factor 1 alpha, a transcription 
factor that is infrequently mutated (~1%) in HNSCC [10,97,98]. The functional significance of 
these mutations, and whether they play a role in cetuximab resistance in the CtxR 3 cells, is 
unknown. 
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PE/CA-PJ49 CtxR 4 
EIF1AX, one of the five genes that is mutated in only the CtxR 4 cells (Table 3.2), 
encodes eukaryotic translation initiation factor 1A, X-linked, a component of the translation 
preinitiation complex [99,100]. This gene is rarely altered (~2%) in HNSCC, and the majority of 
the alterations are deep deletions [10,97,98]. However, in papillary thyroid cancer, the majority 
of the alterations are mutations [97–99]. Though these mutations are uncommon (1.21% of the 
496 cases included in the TCGA analysis), it was suggested that EIF1AX could be an oncogenic 
driver in papillary thyroid cancer (PTC) due to its near-mutual exclusivity with KRAS and BRAF 
mutations and its high rate of alteration (48%) in uveal melanomas with disomy 3 [99,101]. 
EIF1AX mutations were also identified, this time co-occurring with RAS mutations, in poorly 
differentiated thyroid cancers (PDTC) and anaplastic thyroid cancers (ATC) [100]. However, 
these mutations occur near the N-terminus of the protein in both PTC and uveal melanoma 
[99,101], and at a hotspot splice acceptor site (A113splice) in PTDC and ATC [100], whereas the 
mutation identified in the CtxR 4 cells (p.K56N) occurs at a different location; thus, the 
functional significance of this mutation is unknown. 
PIK3R2 encodes p85β, a regulatory subunit of PI3K that is rarely mutated in HNSCC 
(~1%) [10,97,98,102]. The functional significance of the non-frameshift substitution 
(c.700_702CGT) identified in the CtxR 4 cells is unknown; however, in a study focusing on 
mutations in PIK3R2 and other PI3K pathway-associated genes in endometrial cancer, it was 
suggested that PIK3R2 mutations may phenocopy loss of the tumor suppressor phosphatase and 
tensin homolog (PTEN) [102], an alteration that leads to aberrant hyperactivation of PI3K/Akt 
signaling. 
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The presence of a stopgain mutation (p.W563*) in RB1 (which encodes retinoblastoma 
protein) suggests that this tumor suppressor may be functionally inactivated in the CtxR 4 cells. 
As the CDK4/6 inhibitor palbociclib was recently shown to act synergistically with either 
lapatinib or afatinib (tyrosine kinase inhibitors that target EGFR and HER2) to inhibit 
proliferation in HNSCC cell lines [103], it may be worthwhile to test whether co-treatment of the 
CtxR 4 cells with palbociclib has an impact on their response to cetuximab. 
 
3.4 Conclusions and future directions 
As we demonstrated in Chapter 2, alterations that are correlated with cetuximab 
resistance do not necessarily confer resistance to cetuximab (Fig. 2.4); thus, the unique mutations 
identified in the CtxR cells may not play a role in acquired cetuximab resistance. Nonetheless, 
unbiased analyses such as these may uncover novel candidate biomarkers and/or therapeutic 
targets that can then be validated in subsequent functional studies. A reasonable next step to 
follow the UCSF500 analysis would be to determine whether the mutations identified in the CtxR 
cells promote cetuximab resistance by expressing these mutations in cetuximab-sensitive cells, or 
eliminating the mutations from the CtxR cells, and determining whether these interventions 
impact cetuximab response. 
In light of a recent publication focusing on the timing of alterations developed during the 
acquisition of cetuximab resistance in an HNSCC cell line [95], the mutations in genes 
associated with epigenetic regulation, such as NSD1, identified in the targeted sequencing 
analysis may be of particular interest. In the aforementioned study, published by Stein-O’Brien 
and colleagues, a rigorous time course analysis consisting of weekly collection of samples for 
RNA-sequencing and DNA methylation analyses revealed that, while transcriptional changes 
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arose quickly following initiation of cetuximab treatment, stable alterations in DNA methylation 
were observed only after resistance was established, highlighting a difference between adaptive 
responses to treatment and acquired resistance. In addition, we recently reported that the 
chromatin reader protein BRD4 promotes cetuximab resistance in HNSCC cell line models, 
including the PE/CA-PJ49 CtxR cells used in this study [56]. Studying epigenetic alterations in 
cetuximab-resistant cells, whether or not these alterations are related to the mutations detected in 
our targeted sequencing analysis, may identify additional mechanisms of cetuximab resistance 
and potential candidates to target to prevent and/or overcome cetuximab resistance. 
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3.5 Tables 
Table 3.1. SNVs and indels identified in all PE/CA-PJ49 parental and CtxR cell lines.  
 
ARID1A p.A54S NOTCH1 p.P1730L 
ARID1A p.F1457S NOTCH1 p.R365C 
BRCA2 p.I247V PAK1 p.E74D 
CDKN2A p.M52fs PEX11B p.G62V 
CLPTM1L p.316_317del PRDM1 p.R192C 
COL1A1 p.P823A PTPRD p.I1821V 
CREBBP p.S1761* RASA1 c.829_840GTAGAAGATAGA 
FANCG c.176-2A>G RASA1 p.A804fs 
FAT1 c.11049_11050TT RASA1 p.D280delinsDR 
FLCN p.A90S RASA2 p.Q286* 
IPMK p.S261P SYNE1 p.R4152C 
JAK3 p.L1047V TERT promoter 
KMT2D p.M1478fs TSC2 p.R1268C 
† MIR4457 promoter † ZFHX p.1823_1823del 
Exceptions (†) were observed in only the parental and CtxR 3 cells. Abbreviations:  del, deletion; 
fs, frameshift mutation. 
 
 
Table 3.2. SNVs and indels unique to individual cell lines. 
 
Parental CtxR 1 CtxR 3 CtxR 4 
• CHD1 p.K347R 
• CHD5 
p.101_102del 
• EMSY p.E74K 
• GNAQ p.V340F 
• MTOR p.R2443Q 
• MYH9 p.D1293N 
• MYH9 p.E1270K 
• NFKBIA p.E40K 
• PDGFRA p.Y136fs 
• PLCB4 
• KAT6A 
p.1228_1228del 
• NSD1 p.G1132fs 
• CHD5 p.D774E 
• HNF1A 
c.864delinsCC 
• EIF1AX p.K56N 
• PIK3R2 
c.700_702CGT 
• PRKDC exonic 
UNKNOWN 
• RB1 p.W563* 
• ZFHX4 
p.2007_2007del 
Abbreviations:  del, deletion; delins, deletion-insertion; fs, frameshift mutation. 
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Chapter 4:  Materials and Methods 
 
Cell culture 
Cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Corning 10-013-
CM) containing 10% fetal bovine serum (FBS; Gemini Bio-Products #900-108) and 
penicillin/streptomycin (Gibco 15140-122). PE/CA-PJ49 cells were purchased from Sigma-
Aldrich. Cell lines were authenticated by short tandem repeat (STR) analysis performed by the 
University of California, Berkeley DNA Sequencing Facility at least once every 6 months. 
 
Generation of cetuximab-resistant cell lines 
We previously reported generation of the PE/CA-PJ49 cell line models of acquired cetuximab 
resistance [56]. STR analysis was performed on the cetuximab-resistant cell lines to confirm that 
the profiles matched those of the parental cell line. 
 
Dose-response assays 
Cells were plated in 96-well plates and incubated overnight. The next day, the media was 
replaced with media containing the indicated concentrations of drug or an equivalent volume of 
vehicle. After 96 hours of treatment, cells were rinsed with ice-cold phosphate-buffered saline 
(PBS) and stained with crystal violet solution (0.5% crystal violet [Sigma C0775] in 25% 
methanol). To quantify results, crystal violet-stained cells were solubilized in a 1:1 mixture of 
200 mM sodium citrate and 100% ethanol and absorbance at 590 nm was read using a Biotek 
Epoch Microplate Spectrophotometer. Erlotinib (S1023), afatinib (S7810), and lapatinib (S2111) 
were purchased from Selleckchem. Cisplatin was purchased from the University of Pittsburgh 
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Cancer Institute Pharmacy. CBL0137 was provided by Dr. George Stark and Dr. Sarmishtha De 
(Cleveland Clinic). 
 
Gene expression analysis 
RNA was isolated from HNSCC cells using the RNeasy Mini Kit (Qiagen, 74106), according to 
the manufacturer’s protocol (excluding the optional DNase digestion step) and eluted in 
nuclease-free water (Fisher BioReagents, BP2484-50). RNA concentration and purity (OD 
260/280) were determined using the Biotek Epoch Microplate Spectrophotometer. One 
microgram of RNA per sample was converted to complementary DNA (cDNA) in an Eppendorf 
PCR machine using either iScriptTM Reverse Transcription Supermix for RT-qPCR (Bio-Rad, 
#1708840) or iScriptTM cDNA Synthesis Kit (Bio-Rad, #1708890), according to the 
manufacturer’s instructions. Quantitative reverse transcription PCR (qRT-PCR) was performed 
in the CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad) using the iTaqTM Universal 
SYBR® Green Supermix (Bio-Rad, #1725124) according to the manufacturer’s instructions. 
Assay of each sample was performed in technical duplicate. The sequences of the primers used 
are listed in Table 3.1. The delta-delta Ct method was used to determine relative mRNA 
expression (normalized to the reference gene TATA-box-binding protein [TBP]). GraphPad 
Prism was used to conduct Student’s two-tailed t-test to determine whether changes between 
experimental conditions were statistically significant. Controls for each experiment and number 
of biological replicates are indicated in the respective figure legends. 
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Table 4.1. qPCR primers. 
 
Primer Name Sequence 
IL6 forward GGTACATCCTCGACGGCATCT 
IL6 reverse GTGCCTCTTTGCTGCTTTCAC 
IL6R forward AGTGTCGGGAGCAAGTTCAG 
IL6R reverse GGCTGCAAGATTCCACAACC 
IL6ST forward AGGACCAAAGATGCCTCAAC 
IL6ST reverse GAATGAAGATCGGGTGGATG 
TBP forward CCCATGACTCCCATGACC 
TBP reverse TTTACAACCAAGATTCACTGTGG 
 
Immunoblot analysis 
Cells for immunoblot analysis were rinsed twice with ice-cold PBS and lysed on ice in 
radioimmunoprecipitation assay (RIPA) buffer (150 mM sodium chloride, 5 mM EDTA pH 8.0, 
50 mM Tris pH 8.0, 1% NP-40 Surfact-Amps Detergent Solution, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate [SDS]) supplemented with cOmplete Protease Inhibitor Cocktail 
(Roche 11836145001) and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche 04 906 837 
001). Cells undergoing lysis were briefly vortexed, then centrifuged for 10 minutes at 13,200 
RCF at 4°C. Supernatants were transferred to fresh 1.7-mL microcentrifuge tubes and protein 
concentrations were determined using Protein Assay Dye Reagent (Bio-Rad #5000006). Lysates 
were mixed with the appropriate volume of 4X sample buffer (230 mM Tris-HCl pH 6.8, 7% 
SDS, 32% glycerol, 0.1% w/v bromophenol blue, 9% β-mercaptoethanol), boiled for 5 minutes, 
electrophoresed on  10% polyacrylamide Tris-glycine gels, and transferred to Immun-Blot PVDF 
membranes (Bio-Rad #1620177) on a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). 
Membranes were then blocked in 5% nonfat dry milk (Apex 20-241) in Tris-buffered saline with 
Tween 20 (TBST) and probed overnight at 4°C with primary antibodies diluted in 2.5% bovine 
serum albumin (BSA; Sigma A3912) in TBST. Primary antibodies used in this study were 
purchased from Cell Signaling Technology (P-STAT3Y705 [#9145, rabbit monoclonal] and 
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STAT3 [#4904, rabbit monoclonal]), Santa Cruz Biotechnology (gp130 [sc-376280, Lot #B1717, 
mouse monoclonal]), and Abcam (β-tubulin [ab6046, rabbit polyclonal]). 
The next day, membranes were washed 5-6 times in TBST, blocked for 15-30 min in 5% 
nonfat dry milk in TBST, and incubated in the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody for 45-90 min at room temperature. Secondary antibodies used in 
this study were purchased from Bio-Rad (Goat Anti-Rabbit IgG (H+L)-HRP Conjugate 
[#1706515] and Goat Anti-Mouse IgG (H+L)-HRP Conjugate [#1706516]). After incubation in 
secondary antibody, membranes were washed 5-6 times in TBST and incubated in the 
chemiluminescent HRP substrate Western Blotting Luminol Reagent (Santa Cruz Biotechnology, 
sc-2048) according to the manufacturer’s instructions. Films (GeneMate F-9024-8X10) were 
scanned at 300 dpi and images were converted to greyscale prior to densitometric analysis using 
ImageJ (National Institutes of Health), but were not otherwise altered. Density values for the 
proteins of interest were divided by those of the total protein (for phosphorylated proteins) or the 
loading control (β-tubulin) (for all other proteins) from the corresponding lane of the same 
membrane. Data were normalized by dividing the values for each sample by the average of those 
for the control samples (controls for each experiment and number of biological replicates are 
indicated in the respective figure legends). GraphPad Prism was used to conduct Student’s two-
tailed t-test to determine whether changes between experimental conditions were statistically 
significant. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Cells were plated at 50,000 cells per well in 24-well culture plates in DMEM supplemented with 
10% FBS and penicillin/streptomycin and allowed to attach overnight. The next day, cells were 
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gently rinsed with sterile PBS and media was replaced with 500 μL DMEM (without FBS or 
penicillin/streptomycin). After 72 hours of incubation, conditioned media were removed and 
centrifuged for 10 min at 10,000 RCF at 4°C. Supernatants were transferred to fresh 1.7-mL 
microcentrifuge tubes and frozen at -80°C for subsequent analysis. The concentration of IL-6 in 
the cell culture supernatants was determined using the Human IL-6 DuoSet ELISA kit (R&D 
Systems DY206) according to the manufacturer’s instructions. Plates were read at 450 nm on the 
Biotek Epoch Microplate Spectrophotometer, with wavelength correction at 540 nm. Assays 
were performed in technical duplicate. The number of biological replicates is indicated in the 
respective figure legends. GraphPad Prism was used to conduct Student’s two-tailed t-test to 
determine whether changes in concentration of secreted IL-6 were statistically significant 
between parental PE/CA-PJ49 cells and PE/CA-PJ49 cells that had acquired resistance to 
cetuximab. 
 
Cytokines 
Recombinant cytokines used in this study were purchased from PeproTech (Recombinant 
Human IL-6 [200-06], Recombinant Human LIF [300-05], and Recombinant Human Oncostatin 
M (209 a.a.) [300-10T]). Lyophilized cytokines were reconstituted in sterile nuclease-free water 
(Fisher BioReagents, BP2484-50) before use.  
 
siRNA transfection 
Cells were plated in DMEM containing 10% FBS and penicillin/streptomycin and allowed to 
attach overnight. The next day, immediately prior to transfection, media was replaced with 
DMEM supplemented with 10% FBS (without antibiotics). A final concentration of 10 nM 
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siRNA (control [nontargeting] siRNA or one of at least two distinct siRNA sequences per target) 
was transfected into cells using LipofectamineTM RNAiMAX Transfection Reagent 
(ThermoFisher Scientific, #13778500) according to the manufacturer’s instructions, using 5 μL 
RNAiMAX in a total volume of 1.5 mL for 6-well plates and 2.5 μL RNAiMAX in a total 
volume of 750 μL for 12-well plates. The siRNA-containing media was replaced with DMEM 
supplemented with 10% FBS and penicillin/streptomycin 4 hours post-transfection. Knockdown 
was validated using qPCR. All siRNAs were purchased from Origene (IL6 Human siRNA Oligo 
Duplex [SR302379], IL6R Human siRNA Oligo Duplex [SR302380], and IL6ST Human siRNA 
Oligo Duplex [SR302381]). 
 
Clonogenic survival assays 
Cells were plated at 250 cells per well in 12-well cell culture plates. The next day, cells were 
treated as indicated for the particular experiment. Media containing vehicle and/or drug was 
replaced every four days. After 12 days of treatment, cells were stained with crystal violet 
solution (0.5% crystal violet [Sigma C0775] in 25% methanol). 
 
 
UCSF500 Cancer Gene Panel 
Genomic DNA was extracted from the PE/CA-PJ49 parental and CtxR cells using the 
Qiagen DNeasy Blood & Tissue kit (Catalog number 69504) according to the manufacturer’s 
instructions, then submitted to the UCSF Clinical Cancer Genomics Laboratory for testing using 
the UCSF500 Cancer Gene Panel. The UCSF 500 Cancer Gene Panel uses capture-based next-
generation sequencing to target and analyze the coding regions (exons) of 479 cancer genes, as 
well as select introns of 47 genes. Target enrichment was performed by hybrid capture using 
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custom oligonucleotides (Roche Nimblegen). Sequencing of captured libraries was performed on 
an Illumina HiSeq 2500 in rapid run mode (2 X 101 bp read length). Sequence reads were de-
duplicated to allow for accurate allele frequency determination and copy number calling. The 
analysis used open source or licensed software for alignment to the human reference sequence 
UCSC build hg19 (NCBI build 37) and variant calling. Common germline polymorphisms were 
eliminated from analysis using the complete list of germline variants from dbSNP. Rare variants 
were reviewed by using a filtering threshold of 0.1% in large population databases 
(gnomAD; https://gnomad.broadinstitute.org/). Additional filtering to eliminate technology 
specific sequencing artifacts was performed before analyzing the data. 
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